A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein
Clinical trial NCT01918254 · COMPLETED
Trial details
- NCT number
- NCT01918254
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-06
- Primary completion
- 2016-10-07
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.